UBS Announces a New Share Repurchase Program of Up to $6B

04:27pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
UBS announces a new share repurchase program for 2022 of up to $6 billion of common stock, valid for two years.
UBS announces a new share repurchase program for 2022 of up to $6 billion of common stock, valid for two years.

Why Sea Limited Inched Higher Today

10:50pm, Monday, 28'th Mar 2022 The Motley Fool
The company is pulling one of its key businesses from the Indian market.
UBS and Credit Suisse have made further progress in how they would stabilise and restructure themselves in a financial crisis, Swiss financial watchdog FINMA said on Thursday.

Trustmark (TRMK) Enters Deal to Sell Corporate Trust Business

02:34pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Trustmark (TRMK) agrees to sell its corporate trust business to The Peoples Bank, the subsidiary of Peoples Financial.
It may take decades for economies to overcome their dependency on fossil fuels, suggesting it's unrealistic for investors to shun the industry, according to strategists at UBS Group AG (NYSE:UBS). As
Western New England Bancorp (WNEB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe

UBS Group (UBS), Mitsubishi to Sell Japanese Realty JV to KKR

01:19pm, Monday, 21'st Mar 2022 Zacks Investment Research
UBS Group (UBS) and Mitsubishi announce the divestiture of their Japanese real estate joint venture to KKR for $2 billion. The deal is set to increase Common Equity Tier 1 capital ratio.
UBS Group (UBS) and Mitsubishi announce the divestiture of their Japanese real estate joint venture to KKR for $2 billion. The deal is set to increase Common Equity Tier 1 capital ratio.

Why MongoDB Stock Popped Today

11:03pm, Friday, 18'th Mar 2022 The Motley Fool
Wall Street is growing more bullish on the database software provider's prospects.
UBS' stock (NYSE: UBS) has increased slightly YTD as compared to the 9% drop in the S&P500 over the same period. Further, at its current price of $18 per share, it is trading about 10% below its fair
Futures Drift Lower After Kremlin Dashes Ukraine Peace Hopes; Curve Inversion Persists After yesterday''s explosive session, which saw stocks trade in violent kneejerk response to conflicting headlines out of Ukraine at first, only to post the biggest ever post FOMC reversal, as markets realized that the Fed''s overly hawkish ambitions are too great and doom the rapidly slowing economy to an accelerated recession, overnight trading has been positively subdued with emini S&P futs trading in a tight 20 point range between 4,340 and 4,360 until 6 am ET, when European stocks turned negative and US equity futures suddenly dropped as much as 0.5%, after the Kremlin said reports of major progress in Ukraine talks are "wrong" and Kremlin spokesman Dmitry Peskov dismissed reports that the warring parties are moving toward a settlement, blaming Kyiv for slowing the negotiations, crippling any hope for a quick ceasefire deal and adding to worries about the outlook for economic growth as the Federal Reserve’s campaign against inflation gets underway.
UBS Group and UBS AG (UBS) says that UBS Asset Management has agreed with its JV partner, Mitsubishi Corporation, to sell Mitsubishi Corp.-UBS Realty Inc. to KKR & Co
UBS Slams Wall Street Push To Include Defense Stocks In ESG Funds Considering the fact that M&A advisors and investment bankers typically encourage whatever idea their clients are pushing no matter how ludicrous, the fact that one bank is speaking out against a push to slap an ''ESG'' label on defense stocks is remarkable. And yet, here we are . On Wednesday, Vicki Kalb, the London-based head of ESG research for Europe, the Middle East and Africa at UBS, insisted that the debate over slapping an ESG label on weapons-makers "misses the point". While some banks have already moved to slap an ESG label on certain defense stocks, citing the urgency of the war in Ukraine, these decisions are "essentially meaningless" and risk undermining the industry''s credibility in the eyes of clients, as she explained. "There is a lot of emotion clouding the debate and not necessarily rigorous analysis," she said in an interview. "The ESG issues that tend to get attention tend to resonate emotionally." […
UBS is maintaining its buy rating on Biogen (BIIB) despite Tuesday announcement the biotech is taking sole commercial rights to Alzheimers treatment Aduhelm (aducanumab) from Eisai.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE